Guardant Health, Inc. (GH) is a Medical diagnostics research company in the Healthcare sector, listed on Nasdaq.
This page provides the complete earnings calendar, dividend schedule, and financial data for Guardant Health, Inc. in 2026. The next earnings report is expected on October 29, 2026.
Missed consensus estimates for EPS, Guardant Health posted EPS of $-0.90 versus an estimate of $-0.7618, while revenue of $334.98 million exceeded estimates by 6.6%. In the prior quarter EPS also missed expectations while revenue came in ahead of estimates.
Dividend calendar
No dividend history available.
EPS (Earnings Per Share)
Revenue
Company profile
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
